Exane Derivatives’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Exane Derivatives’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-28	Closed	-$19	–	982
2020 Q4	$19	Hold	28	–	–	﹤0.01%	822
2020 Q3	$63	Hold	28	–	–	﹤0.01%	736
2020 Q2	$100	Hold	28	–	–	﹤0.01%	667
2020 Q1	$106	Hold	28	–	–	﹤0.01%	674
2019 Q4	$98	Buy	+28	New	+$73	﹤0.01%	656

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Exane Derivatives's BMY.RT Position: Q1 2021 in Review

Exane Derivatives sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 28 shares — an estimated $19 sold.

Exane Derivatives first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $106 in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Exane Derivatives reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Exane Derivatives sold 28 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $19.
Exane Derivatives first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Exane Derivatives's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $106 in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.